Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9% - What's Next?

Key Points

• Dianthus Therapeutics' stock price fell 4.9% to $37.02, with trading volume down 84% compared to its average.
• Despite the recent decline, Wall Street analysts maintain a consensus "Buy" rating for Dianthus, with an average target price of $61.57.
• The company reported disappointing earnings, with a loss of ($0.88) per share, missing expectations by $0.02, and a negative net margin of 2,364.56%.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price dropped 4.9% on Thursday . The stock traded as low as $37.34 and last traded at $37.02. Approximately 66,327 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 416,429 shares. The stock had previously closed at $38.93.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several research analyst reports. Stifel Nicolaus upped their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, September 12th. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, September 8th. Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 9th. Finally, Wedbush upped their target price on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Friday, September 12th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average target price of $61.57.

Dianthus Therapeutics Stock Down 5.6%

The stock's fifty day moving average price is $27.63 and its two-hundred day moving average price is $21.96. The company has a market capitalization of $1.18 billion, a PE ratio of -11.32 and a beta of 1.57.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.15% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of DNTH. Vestal Point Capital LP raised its stake in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. RA Capital Management L.P. increased its stake in shares of Dianthus Therapeutics by 53.6% during the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after purchasing an additional 1,000,333 shares in the last quarter. Candriam S.C.A. bought a new position in shares of Dianthus Therapeutics during the first quarter valued at approximately $4,510,000. Octagon Capital Advisors LP increased its stake in shares of Dianthus Therapeutics by 11.0% during the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after purchasing an additional 231,500 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after purchasing an additional 149,200 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.